Sigilon Therapeutics, Inc. EBITDA Margin 2021-2023 | SGTX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Sigilon Therapeutics, Inc. (SGTX) over the last 10 years. The current EBITDA margin for Sigilon Therapeutics, Inc. as of June 30, 2023 is .
| EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2023-06-30 | $0.02B | $-0.03B | -161.11% |
| 2023-03-31 | $0.02B | $-0.04B | -240.00% |
| 2022-12-31 | $0.01B | $-0.04B | -323.08% |
| 2022-09-30 | $0.01B | $-0.05B | -433.33% |
| 2022-06-30 | $0.01B | $-0.06B | -630.00% |
| 2022-03-31 | $0.01B | $-0.07B | -690.00% |
| 2021-12-31 | $0.01B | $-0.07B | -740.00% |
| 2021-09-30 | $0.01B | $-0.07B | -591.67% |
| 2021-06-30 | $0.01B | $-0.06B | -457.14% |
| 2021-03-31 | $0.01B | $-0.06B | -438.46% |
| 2020-12-31 | $0.01B | $-0.05B | -392.31% |
